Contract drug research firm Parexel International is exploring a sale, sources familiar with the matter told Reuters on Monday.
Boston-based Parexel had a market value of about $3.51 billion as of Friday’s close. The company’s stock rose as much as 10.2 percent to $75.87 in morning trading.
The Wall Street Journal reported the talks, saying Parexel is working with investment bankers to sound out potential buyers, including private-equity firms.
The company did not immediately respond to a request for comment.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
